智通财经网·2025-06-20 14:00Core Insights - The recent personnel changes at the FDA's CBER have caused fluctuations in the stock prices of gene editing companies, with a notable decline in Capricor Therapeutics due to its association with the suspended officials [1][2] Group 1: Personnel Changes - The CBER's cell and gene therapy department experienced significant personnel changes, with the director Nicole Weldon and her deputy Rachel Anatol being placed on administrative leave [1] - These changes occurred shortly after the appointment of the new CBER director, Vinay Prasad, who replaced the previously departed Peter Marks [1] - The HHS spokesperson indicated that there were management philosophy disagreements between the suspended officials and Prasad [1] Group 2: Market Reactions - Despite the turmoil at CBER, leading gene editing companies such as Editas Medicine, Intellia Therapeutics, Beam Therapeutics, and CRISPR Therapeutics saw their stock prices rise initially [2] - Conversely, Capricor Therapeutics, which is advancing the cell therapy deramiocel for Duchenne muscular dystrophy, experienced a stock price drop of over 10% due to the involvement of the suspended officials in its drug application process [2]